Salute e Benessere

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class…

Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipelineAcquisition supports Sanofi's portfolio growth strategy and complements 30-year heritage in rare diseases and proven industry leadership in immunology and inflammation For each Inhibrx share, Inhibrx shareholders will receive $30.0 in cash, a contingent value right (CVR) of $5.0 and 0.25 shares of a new publicly traded company that will retain Inhibrx's...
Nasdaq GlobeNewswire
23/01/2024

First Implantation of VasQ External Support Device in Greece

"International collaboration between care providers and industry partners is key for raising the standard of care in vascular access with innovations like VasQ for End-Stage Renal Disease patients, not just in Greece, but around the world." said Dr. Mallios about the landmark case. "International collaboration between care providers and industry partners is key for raising the standard of care in vascular access with innovations like VasQ for End-Stage Renal Disease patients, not…
PR Newswire
23/01/2024

iThemba LABS ready to start production of Strontium-82 and Germanium-68 using…

Successful completion of contractual site acceptance tests, with 70 MeV cyclotron now fully operational Louvain-la-Neuve, Belgium, January 23, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical production solutions, is pleased to announce that the Cyclone ®70 system installed at the iThemba Laboratory for Accelerator Based Sciences (iThemba LABS) in Cape Town, one of the...
Nasdaq GlobeNewswire
23/01/2024

Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US…

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION23 January 2024, 07:00 am CET DSMB irates DSR 2.0 as safe following review of data from non-randomized cohortData from non-randomized cohort confirms dramatic improvement in diuretic response and at least 95% reduction in loop diuretic requirements up to almost four months after last DSR therapyFirst patient enrolled in randomized controlled cohort expected in Q1 2024 Ghent, Belgium – 23 January 2024...
Nasdaq GlobeNewswire
23/01/2024

2024 Japan Prize Laureates Announced

Prof. Sir Brian J. Hoskinshttps://cdn.kyodonewsprwire.jp/prwfile/release/M000319/202401155280/_prw_PI4fl_MnpACdsk.jpg Prof. SirBrian J. Hoskins https://cdn.kyodonewsprwire.jp/prwfile/release/M000319/202401155280/_prw_PI4fl_MnpACdsk.jpg Prof.John Michael Wallace https://cdn.kyodonewsprwire.jp/prwfile/release/M000319/202401155280/_prw_PI3fl_RS9kF6a4.jpg - Fields of Medical Science and Pharmaceutical Science Prof.Ronald M. Evans ...
PR Newswire
23/01/2024

BioSenic files for additional patent protection following new clinical evidence…

PRESS RELEASE – INSIDE INFORMATIONFollowing a post-hoc analysis of a Phase 3 trial demonstrating pain relief in patients with severe knee osteoarthritis, Biosenic applied for an international patent to support the newly focused indication of JTA-004.Mont-Saint-Guibert, Belgium, January 23, 2024, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS),the clinical-stage company focused on serious autoimmune and inflammatory diseases and cell therapy, today announces the...
Nasdaq GlobeNewswire
23/01/2024

Genmab Announces Decision in Arbitration Appeal under License Agreement with…

Company Announcement COPENHAGEN, Denmark; January 23, 2024 –Genmab A/S (Nasdaq: GMAB) announced today that the appeal arbitrator in its second arbitration arising under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab has denied Genmab's appeal.As a result, the dismissal of Genmab's claims in the second arbitration is now concluded. Genmab had appealed the tribunal's two-to-one decision dismissing Genmab's claims on the basis that the claims should have...
Nasdaq GlobeNewswire
23/01/2024

Rehabilitation Equipment Global Market to Showcase Growth at a CAGR of ~5% by…

Key Takeaways from the Rehabilitation Equipment Market Report Key Takeaways from the Rehabilitation Equipment Market Report To read more about the latest highlights related to the rehabilitation equipment market, get a snapshot of the key highlights entailed in theGlobal Rehabilitation Equipment Market Report Rehabilitation Equipment Overview Rehabilitation equipment plays a pivotal role in restoring and enhancing the physical abilities of individuals recovering from...
PR Newswire
22/01/2024

Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032…

Key Takeaways from the Non-Alcoholic Fatty Liver Disease Market Report Key Takeaways from the Non-Alcoholic Fatty Liver Disease Market Report Discover which therapies are expected to grab the major NAFLD market share @Non-Alcoholic Fatty Liver Disease Market Report Non-Alcoholic Fatty Liver Disease Overview Non-alcoholic fatty liver disease (NAFLD) is a comprehensive term encompassing a range of liver conditions involving the accumulation of fat, spanning from basic...
PR Newswire
22/01/2024

Latest Phase III trial data investigating Cabometyx® in combination with…

Detailed top-line results from Phase III CONTACT-02 trial demonstrated statistically significant progression-free survival benefit for combination of Cabometyx ®and atezolizumab in metastatic castration-resistant prostate cancer Four-year extended follow-up data from landmark Phase III CheckMate -9ER trial reinforce sustained long-term efficacy benefits for the combination of Cabometyx ®and nivolumab versus sunitinib in advanced renal cell carcinomaPARIS, FRANCE, 22 January 2024...
Nasdaq GlobeNewswire
22/01/2024

Endo's Paladin Labs Announces Launch of XCOPRI® (cenobamate tablets) in Canada

XCOPRI received favourable recommendations for public reimbursement from the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d'excellence en santé et en services sociaux (INESSS) in 2023. Paladin Labs continues to work with federal, provincial, and territorial government payers across Canada and their negotiating body, the pan-Canadian Pharmaceutical Alliance, to help appropriate patients gain access to XCOPRI as soon as possible. XCOPRI received...
PR Newswire
22/01/2024

Evaxion Announces Completion of ADS Ratio Change

/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company's previously disclosed change to its ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), has been made effective. The ratio has changed from one (1) ADS representing one (1) ordinary share to a new ADS Ratio of one (1) ADS representing ten (10) ordinary shares...
Nasdaq GlobeNewswire
22/01/2024

ClearPoint Neuro Announces First EU MDR Certification Success and Approval to…

®MR Hand Drill and SmartTip ®MR Drill Kit. Additionally, the Company received updated certification from its Notified Body allowing for shipment of products manufactured at its new Carlsbad, California facility to Europe. European Medical Device Regulation 2017/745 (EU MDR), the new medical device regulation applicable in Europe, replaces the previous Medical Device Directive 93/42/EEC (MDD) regulation. With the introduction of EU MDR, the EU is placing greater emphasis on safety...
Nasdaq GlobeNewswire
22/01/2024

Oxurion Announces New Strategic Orientation to De-risk and Diversify

Leuven, BELGIUM, 22 January 2024 9:00 PM CET– Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announced today its new corporate strategy to further diversify its activities by actively considering M&A opportunities, specifically in the healthcare sector. Pascal Ghoson, CEO of Oxurion, states,“ Oxurion today lays out its new corporate strategy, which is designed to further diversify and de-risk its ongoing activities. Starting March 2024,...
Nasdaq GlobeNewswire
22/01/2024

Building the healthy workforce of tomorrow: Health Assured launches new…

"With greater access to wellbeing support, the pressure is reduced on our National Health Service, individual recovery rates are improved and the impact of long-term health and mental health conditions on the workplace can be lessened. People returning from long-term absence can have significant concerns or fears around returning to the workplace, so having effective support in place will help to break down these barriers, making the workplace accessible to all." "With greater…
PR Newswire
22/01/2024

ONWARD® to Participate in Basel Healthtech Conference 2024

CEO Dave Marver will discuss the Company's leadership in health technology, including spinal cord stimulation with brain-computer interfaces The conference takes place January 25-26, 2024 in Basel, Switzerland. CEO Dave Marver will participate in 1:1 meetings with investors and partners to discuss the Company's leadership in digital health, including use of implanted brain-computer interface (BCI) technology paired with ONWARD ARC-IM Therapy. *All ONWARD devices and therapies, including...
Nasdaq GlobeNewswire
22/01/2024

Global Urinary Tract Infection (UTI) Treatment Market is expected to Reach US$…

Request Exclusive Sample Report: Urinary Tract Infection (UTI) Treatment Industry Strategic Insights, https://www.futuremarketinsights.com/reports/urinary-tract-infections-market Request Exclusive Sample Report: Urinary Tract Infection (UTI) Treatment Industry Strategic Insights,https://www.futuremarketinsights.com/reports/urinary-tract-infections-market The urinary tract infection treatment market is poised for substantial growth in the foreseeable future, attributed to factors...
PR Newswire
22/01/2024

Parenteral Packaging Market Valuation to Total US$ 20,115.6 Million by 2034 Amid…

Prefilled syringes remain the most sought-after products in the market, and the trend will likely continue during the assessment period. The target segment is projected to account for a prominent value share of 39.6% by 2034. Prefilled syringes remain the most sought-after products in the market, and the trend will likely continue during the assessment period. The target segment is projected to account for a prominent value share of39.6%by 2034. Request Exclusive Sample Report:...
PR Newswire
22/01/2024

Contract Research Organization Services Market / CRO Services Market Worth…

Browse in-depth TOC on "Contract Research Organization Services Market / CRO Services Market" Browse in-depth TOC on "Contract Research Organization Services Market / CRO Services Market" 626 - Tables 57 - Figures 507 - Pages Contract Research Organization Services Market / CRO Services Market Scope: Data management subsegment is the fastest-growing of the CRO Services market by type Among the type subsegments, the market is segmented as Clinical Research Services,...
PR Newswire
22/01/2024

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2…

First enrollment takes place at Erasmus Medical Center in Rotterdam, Netherlands AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) today announced that the first subject has been enrolled at Erasmus Medical Center (“Erasmus MC”) in a Phase 1b/2 clinical trial combining AIM's Ampligen ®(rintatolimod) with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi ®(durvalumab) for the treatment of late-stage pancreatic cancer (the “DURIPANC Study”). Data strongly...
Nasdaq GlobeNewswire
22/01/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 22 January 2024– On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under…
Nasdaq GlobeNewswire
22/01/2024

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company's strategy is focused on advancing the Phase 2 development of its three active immunotherapiesActive immunotherapy now considered to be the optimal approach for precision prevention of neurodegenerative diseasesLausanne, Switzerland, January 22, 2024– AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the...
Nasdaq GlobeNewswire
22/01/2024

Heart Failure start-up, Acorai, closes oversubscribed $4m funding round

Acorai in 2024 Acorai in 2024 After designation as a Breakthrough Device by the US FDA inAugust 2023, Acorai started its global clinical study, CAPTURE-HF, and aims to have its monitoring system ready for clinical use. Concluding in 2024, the study aims to demonstrate the performance of the device through a 1200-patient catheterization study. The Chief Clinical Advisor to Acorai, Dr Andrew J Sauer, commented, "With CAPTURE-HF, the team has really focused on the science to enable...
PR Newswire
22/01/2024

BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug…

The pivotal Phase 3 trial with BNT323/DB-1303 follows positive Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced solid tumorswith early signs of anti-tumor activity in heavily pretreated patients with HER2-low and HER2-positive breast cancerThe trial is expected to enroll 532 patients with Hormone Receptor-positive (“HR+”) and HER2-low metastatic breast cancer progressing on hormone therapy at clinical trial sites...
Nasdaq GlobeNewswire
22/01/2024
Altri  Comunicati